[UPDATE] Ordinary Rebalance | Solactive Genomics Index | Effective Date 13th November 2023
In the ordinary rebalance, the following composition will be implemented effective open 13.11.2023:
10X GENOMICS INC |
2SEVENTY BIO INC-W/I |
AGILENT TECHNOLOGIES INC |
ALLOGENE THERAPEUTICS INC |
ALNYLAM PHARMACEUTICALS INC |
ARROWHEAD PHARMACEUTICALS INC |
AVIDITY BIOSCIENCES INC |
BEAM THERAPEUTICS INC |
BIO-TECHNE CORP |
BIOMARIN PHARMACEUTICAL INC |
BIONTECH SE |
BLUEBIRD BIO INC |
CAREDX INC |
CARIBOU BIOSCIENCES INC |
CRISPR THERAPEUTICS AG |
EDITAS MEDICINE INC |
FULGENT GENETICS INC |
GENSCRIPT BIOTECH CORP |
GILEAD SCIENCES INC |
ILLUMINA INC |
INTELLIA THERAPEUTICS INC |
LEGEND BIOTECH CORP |
LYELL IMMUNOPHARMA INC |
MODERNA INC |
MYRIAD GENETICS INC |
NATERA INC |
PACIFIC BIOSCIENCES OF CALIFORNIA INC |
POSEIDA THERAPEUTICS INC |
QIAGEN NV |
REGENXBIO INC |
ROCKET PHARMACEUTICALS INC |
SANA BIOTECHNOLOGY INC |
SAREPTA THERAPEUTICS INC |
TAKARA BIO INC |
ULTRAGENYX PHARMACEUTICAL INC |
UNIQURE B.V. |
VERACYTE INC |
VERTEX PHARMACEUTICALS INC |
VERVE THERAPEUTICS INC |
VIR BIOTECHNOLOGY INC |